

Hidden Gems Webinar Presentation

Emyria Limited (ASX: EMD) ("Emyria", or the "Company") delivering and developing new treatments for mental health and select neurological conditions, is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, to be held Friday 6th September 2024 from 12:30pm AEST.

Managing Director, Michael Winlo will provide an overview of the Company including interim clinical results relating to the Company's PTSD treatment program and strategy for future growth.

To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

https://us02web.zoom.us/webinar/register/WN_H7T27cejRI2ttDwY_pp48g#/registration

A recorded copy of the webinar will be made available following the event.

-ENDS-

This release has been approved by the Board of Emyria.

For further information, investment opportunities, or more about our approach to mental health treatment, please contact:

Managing Director
Michael Winlo
+61 (0) 8 6559 2800
mwinlo@emyria.com

Media Contact
Haley Chartres
+61 (0) 423 139 163
haley@hck.digital

Corporate Advisor
Sufian Ahmed
+61 (0) 412 316 162
info@62capital.com.au

Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and drug development:

generates

Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD ¹

informs

Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients and used to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

EMYRIA'S INTERACTIVE INVESTOR HUB


[Investorhub.emyria.com](https://investorhub.emyria.com) Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Risks associated with the use of MDMA

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. These effects of MDMA are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision.



Hidden Gems Webinar

emyria

ASX: EMD

Delivering and developing new treatments for PTSD

06 September 2024

DISCLAIMER

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. These effects are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision.

EMYRIA (ASX: EMD) CORPORATE DETAILS


SUBSTANTIAL SHAREHOLDERS

Shareholder	%
Tenmile	5.8%
Top 20	56.3%



ASX: EMD TRADING INFORMATION

Share Price	A\$0.046
6-Month low / high	A\$0.032 / 0.07
Shares Outstanding	349,226,509
Market Capitalisation	A\$18.8M
Cash (30 June 2024)	A\$1.9M*



Mental health now Australia's #1 chronic health problem

Figure 2: Types of serious illness by age and sex, 2009 to 2021





Figure 2: Estimated proportion of Australians reporting serious illnesses, by sex and age group, 2009–2021.

<https://www.aihw.gov.au/mental-health>

EMYRIA'S MISSION



*To first **transform PTSD care** by **developing and delivering** new **treatments** that profoundly enhance patient **well-being** and **quality of life.***

TACKLING POST TRAUMATIC STRESS DISORDER

A chronic, debilitating condition that can develop after experiencing, or repeatedly being exposed to, traumatic events

7%

of adults ¹
1.5m Australians
23m Americans

2x

as common in
first responders ²

\$232

B/yr

Treatment costs
in USA alone ³

In Australia,
workers
compensation
“mental health”
claims can total
over \$300,000 ⁴

SOURCES:

1. <https://www.phoenixaustralia.org/ptsd-awareness-day/>

2. Obuobi-Donkor G, et al A Scoping Review on the Prevalence and Determinants of Post-Traumatic Stress Disorder among Military Personnel and Firefighters: Implications for Public Policy and Practice. Int J Environ Res Public Health. 2022 Jan 29;19(3):1565. doi: 10.3390/ijerph19031565.

3. <https://www.apa.org/monitor/2023/01/staggering-ptsd-costs>

4. From CommCare conference August 2024



CURRENT PTSD TREATMENT APPROACHES

If patients can access the care they need, not all patients will respond

Biological



Managed by specialists

Medications (Sertraline, Paroxetine)

*Variable response, side effects
No new drug approval in **20+ years!**¹*

Psychological



Managed by therapists

Therapies (CBT², Prolonged Exposure)

*Variable response &
can have high drop-out rates*

WE NEED A NEW PARADIGM...

Could we more deeply integrate the benefits of both approaches?

Biological



Psychological



Specialists

Therapists

MDMA-ASSISTED THERAPY (MDMA-AT) FOR PTSD

2-3 medication sessions with **supportive therapy** to enhance clinical response

MDMA-assisted therapy

MDMA

(3,4-methylenedioxymethamphetamine or “ecstasy”)




Supportive, trauma-informed psychotherapy

MDMA produces feelings of emotional connection, openness and fear extinction.

Allows patients to discuss challenging material.

***Future state:
Improvement and innovation
in both fields***

MDMA-AT FOR PTSD PROMISING OUTCOMES IN PHASE 3 TRIALS



MDMA-AT significantly reduced PTSD symptoms, as shown by the change in CAPS-5 total severity score from baseline to 18 weeks after baseline

Key benefits after 3 DOSING SESSIONS


86.5% of MDMA-AT participants reported improvement, compared to 69% in placebo group.

71.2% of MDMA-AT participants no longer met PTSD criteria, compared to 47.6% in the placebo group.

Further enhancements reported in family, social, and professional aspects.

MDMA-AT VS GOLD STANDARD CARE FOR PTSD

MDMA-AT showed high remission success and low dropout rates



References: L. Schoenmaker 2015, J. Schurr 2022, M. Schoefer 2019, S. Mitchell 2023, G. Mitchell 2023

SOURCES:

- 1. Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27, 1025-1033 (2021)
- 2. Mitchell, J.M., et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med (2023). <https://doi.org/10.1038/s41591-023-02565-4>



A large crowd of people is seen from behind, filling a street or festival area. The scene is bathed in warm, golden light, likely from the sun being low in the sky, creating a strong lens flare in the upper right corner. The crowd is dense, and the background shows buildings and streetlights, suggesting an urban setting.

3 Reasons:

**Why Emyria has such a remarkable
opportunity to lead this important
new approach to PTSD**

(1) AUSTRALIA'S UNIQUE REGULATORY ENVIRONMENT

Australia has a significant, world-wide, first-mover advantage



Home > News and Community > Media releases

Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists


Published: 3 February 2023

Listen Print Share



From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

1 July 2023¹



Legal access possible



The Washington Post
Democracy Dies in Darkness

HEALTH Health Care Medical Mysteries Science Well+Being


FDA rejects first psychedelic to treat PTSD, calling for more study

In June, an independent committee of experts convened by the Food and Drug Administration recommended against approving the treatment.

8 min 235



9 August 2024²



? 5 years

(2) EMYRIA HAS SOLVED THE COMPLEX DELIVERY CHALLENGES



Skilled & trained **multi-disciplinary** team (20+)



Secure supply of **GMP-grade** medicines



Evidence-based, **ethics-endorsed** protocols



A **method** for patients to fund treatment



Fit-for-purpose facilities



empax centre A WORLD-CLASS FACILITY



Dedicated therapy rooms




Supported with technology to optimise evidence gathering and patient experience

READY TO SCALE...

(3) EMYRIA'S PTSD PROGRAM IS DELIVERING PATIENT OUTCOMES

60% average improvement in PTSD symptoms (as measured with the PCL-5¹)




All patients

demonstrated a clinically - significant improvement in symptoms (change of 12 points of more)²

50% of patients to remission (PCL-5 score <30)²

(3) EMYRIA'S PTSD PROGRAM IS DELIVERING PATIENT OUTCOMES


50% average improvement in Quality of Life (as measured with the ReQoL-5¹)



75% of patients had a clinically - significant improvement in quality of life scores (> 10 point change)²


CASE STUDY | KATE (*First Responder*)

- Presented 2018
- PTSD due to cumulative workplace traumas
- Myriad of **therapies**: EMDR, in-vivo, ACT, CBT, mindfulness, somatic exercises, TMS, imagery rescripting, nightmare rescripting
- Different psychotropic **medications**
- Stuck, terrified and tortured by her unrelenting symptoms and her psychological defenses - anticipated fear of the fear and blocks to processing
- Despite all efforts and commitment, she was **treatment** and **therapy resistant**



CASE STUDY | KATE | PCL-5 Trends Over 5 Years


2 years



A large crowd of people walking down a city street at sunset. The scene is filled with people, and the warm, golden light of the setting sun creates a hazy, atmospheric effect. The text is overlaid on the upper portion of the image.


**Creating global patient impact and
long-term value**

CREATING LONG-TERM VALUE





Catalysts:

Payer Engagement



CREATING LONG-TERM VALUE



Catalysts:




OUR NOVEL DRUG DISCOVERY PIPELINE


We have a large, **patented** library of MDMA-inspired candidates



New medications




MDMA as inspiration



Our leading development series:

EMD-MX1


Increase versatility of drug-assisted therapy for mental health disorders



We have created MDMA-like molecules with rapid *and* extended half-lives.

EMD-MX2

Help symptoms of L-DOPA induced dyskinesia (LID), affecting up to 80% of Parkinson's patients



We have created selective serotonin and dopamine releasers.

Program Highlights

- “Next-generation” psychedelic-assisted therapies
- Select neurological conditions
- Recently awarded major \$500k grant to advance program¹

OUR WORLD-CLASS TEAM | CLINICS, DRUG APPROVALS, DATA



Greg Hutchinson
**Non-Executive
Chairman**

- **Health Service Expansion**
Expertise: CEO Sonic HealthPlus and 5D Clinics; leads 40+ clinics



Dr Michael Winlo
Managing Director

- **Clinical Data Expertise:**
Ex-Palantir healthcare lead, merging Medical Doctor and Stanford MBA



Dr Karen Smith
**Non-Executive
Director**

- **Biopharma Authority:** 100+ clinical trials and 20+ regulatory approvals; Former Chief Medical Officer and Global Head of R&D at Jazz Pharma



Dr Mohit Kaushal
**Non-Executive
Director**

- **Health IT Strategist:**
Key role in Oak Street Health's \$10.6B acquisition by CVS Health; Served in Obama's Health IT task force; Adjunct Professor at Stanford



Prof Sir John Tooke
**Non-Executive
Director**

- **Clinical Service & Health Payer Expertise:** Former President of the Academy of Medical Sciences, influential roles at BUPA and past advisor to Google DeepMind



KEY MILESTONES


Next 6 months

SERVICE DELIVERY



- Major hospital partnerships
- Major payer engagement
- Launch 2nd psychedelic-assisted therapy program
- Expand Empax Centre locations

Supported by growing **service revenues**




DRUG DEVELOPMENT

- ✓ Clear search report for MDMA analogue patent family
- ✓ Advance to Tier 3 with NIH program
- Commercialisation agreement with UWA

Fully funded by **grants**¹

BEYOND PTSD

Emyria's model is poised to tackle additional unmet needs in mental health



EMYRIA (ASX: EMD)

CONTACT INFORMATION

Michael Winlo	mwinlo@emyria.com
Investors	investors@emyria.com
Media	media@emyria.com
General	info@emyria.com

<https://investorhub.emyria.com/>

